Elpida LLC has registered the combined medicinal product Elpida® Combi. The product is available in film-coated tablets containing three active components: tenofovir 300 mg (NRTI), elsulfavirine 20 mg (NNRTI) and emtricitabine 200 mg (NRTI). This combination is characterized by the absence of cross-resistance, mutual antagonism, cross-toxicity, and one of the main advantages of this combination is the simplification of the dosing regimen and improvement of patient compliance with therapy.